ArticleBMC cancer2025
Exploring the mutational spectrum of key kinase genes PIK3CA, BRAF, EGFR, ALK and ROS1 in oral squamous cell carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mutational insights andFrontiers in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Oral Squamous Cell Carcinoma (OSCC) is the sixth most aggressive type of oral cancer. Mutations in cancer-driving genes such as protein kinase are well known in cancer progression. We selected candidate genes (PIK3CA, BRAF, EGFR, ALK, and ROS1) for mutations exploration in the OSCC patients belonging to Khyber Pakhtunkhwa (KP) through Next Generation-Whole Exome Sequencing (NG-WES) using Formalin Fixed Paraffin Embedded (FFPE) tissue blocks (27 tumor and 7 paired normal) for the 1st time followed by in-silico characterization. A total of 33 mutations were identified which constituted 28/33 (84.84%) SNVs, 4/33 (12.12%) frameshift deletions and 1/33 (3.03%) stop-gain mutation. While, of the 33 mutations, 12.6% (4/33) were novel and had not been previously reported in public mutation databases such as COSMIC or dbSNP. Among the total somatic mutations (24/33; 72.72%), 08/33 mutations were observed in multiple patients. Mutations of the ALK i.e. ALK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.